Antibody polypeptides that antagonize CD40

US9475879B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• Domantis Limited · GB

Inventors

• Anish Suri · Beerse, BE
• Steven Sheriff · Princeton, US
• Suzanne J. Suchard · Wilmington, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Stanley Krystek · Ringoes, US
• James K. Tamura · Yardley, US
• James W. Bryson · Langhorne, US
• Steven Grant · Cambridge, GB
• Philip Drew · Histon, GB

Key dates

• Filing date: Apr 20, 2012
• Grant date: Oct 25, 2016
• Expiry date: Mar 12, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).